Upadacitinib
Educational summary, not a formulary. Dosing is quoted from the Makindo chapters and topics site. The other sections are draft summaries not yet checked line by line against the BNF or SPC. Check dose, indication, interactions and monitoring in the BNF entry for Upadacitinib and local guidelines before prescribing.
Mechanism
JAK1 inhibitor.
Uses
Rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, ulcerative colitis, Crohn disease, atopic dermatitis.
Dosing
No dose is given in the chapters. See the BNF.
Side effects
Infections, herpes zoster, raised lipids, cytopenias, VTE, MACE.
Interactions
CYP3A4 inhibitors and inducers.
Contraindications and cautions
Active infection, severe liver impairment
Monitoring
FBC, LFT, lipids
Pregnancy and breastfeeding
Contraindicated
Renal and hepatic impairment
Avoid in severe liver impairment
Overdose and reversal
Supportive
Special advice
Same MHRA JAK caution groups; screen for TB and hepatitis.
More from the textbook: uses, cautions and other points
- Tofacitinib , upadacitinib , filgotinib | JAK inhibitors (oral) | Fast acting; MHRA - increased risk of VTE , major cardiovascular events, cancer and serious infection: avoid in people over 65, smokers and those with cardiovascular or cancer risk unless no alternative; shingles (vaccinate); raised lipids; teratogenic
Gastroenterology: Anatomy Physiology Pharmacology - Tofacitinib / filgotinib / upadacitinib | Oral JAK inhibitors; MHRA caution over 65, smokers, CV or cancer risk; VTE; shingles; avoid in pregnancy.
Gastroenterology: Inflammatory Bowel Disease - Oral JAK inhibitors - abrocitinib , upadacitinib , baricitinib - effective; MHRA advice: use in people over 65 , smokers, or those with cardiovascular or cancer risk factors only if no suitable alternative (risk of MACE, VTE, cancer, serious infection).
Dermatology: Skin basics, eczema and psoriasis - Abrocitinib / upadacitinib / baricitinib | Oral JAK inhibitors for eczema; caution over 65, smokers, CV or cancer risk.
Dermatology: Skin basics, eczema and psoriasis - JAK (small molecules) | Tofacitinib, baricitinib, upadacitinib, filgotinib | RA, psoriatic arthritis, axial SpA — caution over 65s and smokers (MHRA)
Rheumatology Anatomy Physiology Pharmacology - JAK inhibitors (tofacitinib, upadacitinib) - with MHRA cautions.
Rheumatology: Inflammatory arthritis - Tofacitinib / upadacitinib | JAK inhibitors; VTE, cardiovascular and cancer risk (MHRA); shingles.
Gastroenterology: Anatomy Physiology Pharmacology - Tofacitinib and filgotinib (UC), upadacitinib (UC and Crohn's).
Gastroenterology: Inflammatory Bowel Disease
Where it is discussed in the book
- Gastroenterology: Anatomy Physiology Pharmacology (2 mentions)
- Gastroenterology: Inflammatory Bowel Disease (2 mentions)
- Dermatology: Skin basics, eczema and psoriasis (3 mentions)
- Rheumatology Anatomy Physiology Pharmacology (1 mention)
- Rheumatology: assessment, investigations and drugs (1 mention)
- Rheumatology: Inflammatory arthritis (1 mention)
- ID: Hospital infection, the immunocompromised host, vaccination and public health (1 mention)
- Clinical Immunology: Immune system basics and immunological investigations (1 mention)
- Cell Biology: Cell cycle, signalling, cell death and stem cells (1 mention)